Endometriosis — in which tissue resembling the uterine lining grows outside the uterus — affects approximately 10% of women of reproductive age and is one of the leading causes of chronic pelvic pain and infertility. The condition is strongly heritable, yet the molecular events that allow retrograde endometrial cells to implant and survive on peritoneal surfaces remain incompletely understood. rs3820282 stands out among endometriosis risk variants because functional experiments have revealed its mechanism with unusual clarity: it creates a new binding site for the estrogen receptor¹¹ creates a new binding site for the estrogen receptor
ESR1: estrogen receptor alpha, a transcription factor that mediates the downstream effects of estrogen on gene expression directly within the first intron of WNT4, converting what was a transcriptionally quiet region into an estrogen-responsive switch.

rs3820282 lies on chromosome 1p36.12 within intron 1 of the WNT4 gene, approximately 21 kb from the widely-studied rs7521902. Although both SNPs tag the same 1p36 haplotype block and are in linkage disequilibrium²² linkage disequilibrium
LD: the tendency for nearby variants to be inherited together; variants in high LD are often proxies for the same underlying causal signal in European populations, rs3820282 has emerged from fine-mapping studies as the more direct molecular actor — the variant whose alternative allele appears to alter the DNA sequence itself rather than simply tagging a nearby causal change.

The Mechanism

WNT4 encodes a secreted glycoprotein belonging to the Wnt signaling family, which is essential for the embryonic development of the female reproductive tract from Müllerian duct precursors and for the monthly decidualization of the endometrium. The protein operates downstream of the IHH–COUPTFII pathway³³ IHH–COUPTFII pathway
the Indian Hedgehog – COUP transcription factor II axis, which coordinates progesterone response in endometrial stromal cells during the secretory phase to drive the transformation of endometrial stromal cells into specialized decidual cells — a prerequisite for embryo implantation.

The T allele at rs3820282 changes the intronic sequence from C to T, introducing a high-affinity recognition motif for estrogen receptor alpha (ERα). When estrogen levels peak before ovulation, ERα bound to this newly created site activates WNT4 transcription in the endometrial stroma, producing 1.48–3.27 log2-fold higher WNT4 expression⁴⁴ 1.48–3.27 log2-fold higher WNT4 expression
measured in CRISPR-edited knock-in mouse lines carrying the human T allele; Pavličev et al. 2024 Nature Communications during the proestrus and estrus cycle phases. The downstream effect is a uterine stromal environment with enhanced invasibility — better at accepting an implanting embryo, but also more permissive to attachment by ectopic endometrial fragments shed into the peritoneal cavity during retrograde menstruation.

This same variant simultaneously acts as an expression quantitative trait locus (eQTL)⁵⁵ expression quantitative trait locus (eQTL)
a variant that affects how much RNA is produced from a nearby gene rather than changing the protein sequence for two nearby genes: LINC00339 (a long non-coding RNA, whose expression is decreased by the risk allele) and CDC42 (a Rho GTPase involved in cytoskeletal organization and cell migration, whose expression is increased). Elevated CDC42 activity may further facilitate the migratory behavior of ectopic endometrial cells.

The Evidence

Fine-mapping of the chromosome 1p36 WNT4 region in 930 endometriosis cases and 959 controls⁶⁶ 930 endometriosis cases and 959 controls
Luong et al. Int J Mol Epidemiol Genet, 2013 identified rs3820282 as one of three variants with stronger association than the previously-reported rs7521902, noting its position within recognition motifs for both ESR1 and ESR2 — a direct prediction of the estrogen-receptor mechanism later confirmed experimentally.

In a 7,090-person fine-mapping study⁷⁷ 7,090-person fine-mapping study
Powell et al. Human Molecular Genetics, 2016 (2,594 endometriosis cases, 4,496 controls), rs3820282 showed the strongest association at the 1p36.12 locus for endometriosis (P = 1.84 × 10⁻⁵, OR = 1.244, 95% CI 1.126–1.375), outperforming rs7521902 as a direct disease signal. The same variant was confirmed as an eQTL for both LINC00339 and CDC42 in endometrial tissue.

The functional confirmation arrived in 2024: CRISPR knock-in experiments⁸⁸ CRISPR knock-in experiments
Pavličev et al. Nature Communications, 2024 in mice introduced the human T allele into the equivalent Wnt4 locus. Both independently generated knock-in lines showed significantly higher uterine Wnt4 expression compared to wildtype animals during the estrogen-peak phases (proestrus and estrus), confirming the estrogen-receptor-binding mechanism proposed from human sequence analysis.

A striking feature of rs3820282 is antagonistic pleiotropy across reproductive tissues. The same T allele that raises endometriosis and fibroid risk appears to confer reproductive benefit: across multiple GWAS, the T allele is associated with longer gestation and reduced preterm birth risk. Conversely, the C allele — which is relatively rare in East Asian populations — is the risk allele for pelvic organ prolapse⁹⁹ pelvic organ prolapse
a condition in which the pelvic floor structures weaken and pelvic organs descend into the vaginal canal (OR 1.18, P = 3 × 10⁻²¹). This explains why the T allele has remained common despite its association with endometriosis: in evolutionary terms, the same molecular mechanism that facilitates embryo implantation comes at the cost of ectopic endometrial invasion.

Practical Implications

For women carrying one or two copies of the T allele, the most actionable implication is awareness of endometriosis symptoms and a lower threshold for seeking specialist evaluation rather than accepting menstrual pain as normal. The average diagnostic delay for endometriosis is 4–11 years from first symptoms, driven by normalization of dysmenorrhea and the requirement for laparoscopic confirmation.

The WNT4 locus is also associated with uterine fibroids (leiomyomas) at genome-wide significance. T allele carriers may therefore warrant gynecological evaluation that includes assessment for both conditions — a pelvic ultrasound can screen for both ovarian endometriomas and uterine fibroid burden simultaneously.

No supplement or dietary intervention specifically targeting the estrogen-receptor-WNT4 axis has been studied. Progestin-based hormonal therapies remain the mainstay of endometriosis management and address the progesterone-resistance pathway through which WNT4 dysregulation is thought to act.

Interactions

rs7521902 (WNT4 1p36.12 sentinel): rs7521902 is in moderate-to-high linkage disequilibrium with rs3820282 in European populations, meaning both variants partly tag the same underlying haplotype signal. In populations where LD is lower (East Asian, Brazilian cohorts), rs3820282 may be the more informative marker. Users carrying risk alleles at both loci reflect the same biological signal rather than independent additive contributions.

rs4762326 (VEZT, chromosome 12q23.2): The VEZT locus encodes vezatin, a component of adherens junctions that mediates cell-cell adhesion. VEZT and WNT4 represent two mechanistically distinct pathways to ectopic endometrial implantation — cell adhesion capacity vs. estrogen-driven stromal invasibility. Carrying risk alleles at both loci could compound endometriosis susceptibility through complementary mechanisms, though formal gene-gene interaction data have not been published.

rs1250248 (FN1 — fibronectin 1): An epistatic interaction between the WNT4 locus (rs7521902) and FN1 has been described for ovarian endometriosis (OR 1.56 for the interaction term; Pagliardini et al. 2013, PMID 23142796). Fibronectin is a major extracellular matrix glycoprotein that works alongside cell adhesion receptors; it may interact directly with the WNT4-driven stromal invasibility that rs3820282 mediates.

Protein S — encoded by the PROS1 gene on chromosome 3q11.1 — is one of the body's primary anticoagulant regulators. It circulates in plasma partly free (the active anticoagulant fraction, ~40%) and partly bound to C4b-binding protein (~60%). Free protein S serves as a cofactor for activated protein C (APC)¹¹ activated protein C (APC)
APC degrades the procoagulant factors Va and VIIIa, acting as a molecular brake on the coagulation cascade, preventing excessive fibrin clot formation. Protein S can also inhibit coagulation independently of protein C by directly blocking prothrombinase and tenase complex assembly. The PROS1 Y234C variant (rs387906675) is one of the rarest and most severe single-nucleotide mutations in this gene: homozygous carriers develop protein S activity below 10%²² protein S activity below 10%
Measured in the index patient from Fischer et al., 2010; normal range is roughly 60–140% of mean reference activity, producing life-threatening neonatal thrombosis.

The Mechanism

The c.701A>G transition (plus-strand notation: T>C at rs387906675) changes tyrosine at position 234 to cysteine in the protein S polypeptide chain. Tyrosine 234 is located within the laminin G-type (LG) domain³³ laminin G-type (LG) domain
A structural domain important for protein S binding to C4b-binding protein and factor Xa; point mutations here typically disrupt both secretion and cofactor function of protein S. The introduction of a free thiol group from cysteine in this structurally constrained position disrupts protein folding, likely preventing normal secretion from hepatocytes or degrading the mature protein's ability to bind and activate protein C. The net effect is either absent or non-functional protein S — clinically indistinguishable from a null allele in terms of residual anticoagulant activity.

Heterozygous carriers produce approximately half the normal amount of functional protein S from the intact allele. This partial deficiency (typically 30–60% of normal free protein S activity) is sufficient for most everyday hemostasis but creates a measurable prothrombotic state, especially under provoking circumstances — pregnancy, oral contraceptive use, surgery, prolonged immobility, or intercurrent illness.

The Evidence

The variant was first reported by Fischer and colleagues in 2010⁴⁴ first reported by Fischer and colleagues in 2010
Neonatology 2010, 98(4):337–40; case of an Albanian-origin infant in an infant born of consanguineous parents who presented on day four of life with seizures and hemorrhagic shock. MRI revealed massive intracranial hemorrhage; coagulation studies demonstrated protein S activity below 10%. The infant subsequently developed aortic thrombosis and died on day eight. Post-mortem examination showed diffuse thromboses of intracerebral capillaries, confirming the underlying prothrombotic state produced both thrombotic and hemorrhagic pathology simultaneously — the paradox of severe thrombophilia, where occlusion of small vessels causes ischemic infarction and secondary hemorrhage upstream.

For heterozygous carriers, risk quantification comes from broader protein S deficiency cohort data. A 2025 population-scale JAMA study⁵⁵ 2025 population-scale JAMA study
UK Biobank + NIH All of Us; 600,000+ participants, 18,011 VTE events stratified PROS1 variant risk by mutation class: heterozygous carriers of missense PROS1 variants had OR 1.98 for VTE, while carriers of complete loss-of-function variants (nonsense, frameshift, essential splice site) had OR 14.01. Y234C functionally approximates a loss-of-function allele given residual protein S activity near zero, placing heterozygous carriers toward the higher end of the missense risk spectrum. A Danish family cohort⁶⁶ Danish family cohort
87 PS-deficient participants and relatives; Christensen et al. 2021 found 43% of individuals with coding PROS1 variants experienced at least one VTE, versus 17% in non-carrier family members. Prospective follow-up data estimate an annual first-VTE incidence of ~0.7% in heterozygous protein S deficiency⁷⁷ ~0.7% in heterozygous protein S deficiency
Comparable to other high-penetrance inherited thrombophilias such as protein C deficiency and antithrombin deficiency — roughly 5-fold above the population baseline. Recurrence risk after a first event is substantially higher: 6–10% per year⁸⁸ 6–10% per year.

Practical Implications

For heterozygous carriers who have not had a VTE, the priority is identifying and modifying provoking risk factors — especially estrogen-containing hormonal contraceptives, which independently increase VTE risk 3–5-fold and combine multiplicatively with inherited thrombophilias. Carrier status should be documented prominently in the medical record so that prophylaxis can be given during surgery, prolonged hospitalization, and obstetric care. Direct oral anticoagulants (DOACs — apixaban, rivaroxaban) are now preferred over vitamin K antagonists for most VTE treatment episodes; carriers whose VTE was unprovoked or recurrent should discuss whether indefinite anticoagulation is appropriate.

For homozygous carriers or compound heterozygotes (carrying Y234C on one allele and a different pathogenic PROS1 variant on the other), clinical presentation is often in the neonatal period or early infancy with purpura fulminans, multifocal thrombosis, or intracranial hemorrhage. Emergency management includes fresh frozen plasma (FFP) to restore protein S, followed by long-term anticoagulation and consideration of protein S concentrate where available.

Interactions

The most clinically significant interaction is with Factor V Leiden (rs6025, F5 R506Q)⁹⁹ Factor V Leiden (rs6025, F5 R506Q)
Factor V Leiden renders activated factor V partially resistant to inactivation by activated protein C — since protein S is the cofactor for APC, these two defects are mechanistically synergistic. A documented case of a child with protein S deficiency plus heterozygous Factor V Leiden developed neonatal purpura fulminans despite each defect being individually less severe. Similarly, compound PROS1/PROC mutations (protein S plus protein C deficiency) produce synergistic prothrombotic effects: severe PS deficiency can unmask a pathogenic PROC variant even when protein C activity appears normal by standard testing.

The prothrombin G20210A variant (rs1799963, F2) is the second most common inherited thrombophilia; in combination with protein S deficiency it compounds VTE risk in an additive fashion, justifying a complete thrombophilia panel in any carrier.

to Insulin Resistance

Polycystic ovary syndrome (PCOS) affects 5–15% of women of reproductive age worldwide and is the leading cause of anovulatory infertility. Beyond its reproductive features — irregular cycles, excess androgens, and polycystic ovaries — PCOS is fundamentally a metabolic disorder: 50–70% of affected women have insulin resistance, independent of body weight. Genome-wide association studies in Han Chinese women have identified over a dozen PCOS susceptibility loci, and among them rs4784165 near the TOX3 gene¹¹ rs4784165 near the TOX3 gene
TOX3: TOX High Mobility Group Box Family Member 3, chromosome 16q12.1 stands out for its specific link to the metabolic rather than purely hormonal features of the syndrome.

The Mechanism

TOX3²² TOX3
a high-mobility-group (HMG) box transcription factor originally characterized in neurons encodes a protein that regulates calcium-dependent gene transcription. TOX3 interacts with CREB (cAMP response element- binding protein) and CBP (CREB-binding protein), and knockdown of endogenous TOX3 substantially reduces calcium-induced gene expression. In addition to its neuronal role, emerging evidence places TOX3 in hepatic metabolic regulation: studies suggest TOX3 controls hepatic gluconeogenesis and insulin sensitivity through hepatic transcriptional programs, and that dysregulation of TOX3 exacerbates insulin resistance and glucose intolerance — mechanisms central to both type 2 diabetes and PCOS pathogenesis.

The rs4784165 variant sits in an intronic region of a long non-coding RNA locus (LOC107984901) on chromosome 16q12.1, approximately adjacent to the TOX3 gene. No pathogenic coding mutations have been found in TOX3 in PCOS women, confirming that rs4784165 acts as a regulatory signal³³ rs4784165 acts as a regulatory signal
sequencing of all TOX3 exons and exon-intron boundaries in 200 Han Chinese PCOS women found no pathogenic variants, PMID 25311971 rather than a structural variant. Epigenetic data support this interpretation: Ning et al. 2017 (30 PCOS/30 controls)⁴⁴ Ning et al. 2017 (30 PCOS/30 controls)
European Review for Medical and Pharmacological Sciences found significantly lower TOX3 promoter methylation in PCOS granular cells and serum, leading to reduced TOX3 protein expression — suggesting the variant alters local chromatin accessibility or regulatory element activity near this locus.

The Evidence

The TOX3 rs4784165 G allele was first identified as a PCOS risk allele in a second Han Chinese genome-wide association study by Shi et al. 2012⁵⁵ second Han Chinese genome-wide association study by Shi et al. 2012
Nature Genetics; 1,510 cases and 2,016 controls discovery + independent replication, one of eight newly discovered PCOS loci. The GWAS odds ratio for G allele carriers is approximately 1.15, a modest but consistently replicated effect. A meta-analysis across 47 studies (10,584 PCOS cases, 16,150 controls) estimated OR = 1.08 (95% CI: 1.00–1.16) for PCOS susceptibility.

The clinical significance of this locus extends beyond simple disease susceptibility to metabolic stratification within PCOS. Tian et al. 2020 (2,082 Han Chinese PCOS women)⁶⁶ Tian et al. 2020 (2,082 Han Chinese PCOS women)
Frontiers in Endocrinology found that women carrying at least one G allele (GG + GT) had significantly higher rates of insulin resistance than TT homozygotes (53.3% vs. 48.5%, P = 0.027, OR = 1.27) after adjustment for age and BMI — a dominant model effect. The G allele was also associated with elevated TG/HDL-C ratios, a key atherogenic marker. Across populations, the G allele frequency varies substantially: ~25% in Europeans, ~33% in East Asians, and ~42% in Africans.

In a Saudi Arabian cohort, Bakhashab & Ahmed 2019 (94 PCOS cases, 94 controls)⁷⁷ Bakhashab & Ahmed 2019 (94 PCOS cases, 94 controls)
Bioinformation found significant association between rs4784165 and the combined oligo/amenorrhea plus polycystic ovarian morphology PCOS subgroup, linking this variant to the ovarian structural features of the syndrome as well as metabolic features. Notably, replication of this locus in European populations has not been conclusively demonstrated, suggesting either ethnic-specific genetic architecture or insufficient power in available European cohorts.

Practical Actions

For G allele carriers with PCOS or PCOS-adjacent features (irregular cycles, elevated androgens, insulin resistance), the dominant model association with insulin resistance is the most actionable finding. Insulin resistance in PCOS is independently addressable through genotype-informed supplementation: myo-inositol (the glucose-transporter-linked signaling molecule) at 2–4 g/day has the strongest evidence base for improving insulin sensitivity, ovarian function, and androgen levels specifically in PCOS women with insulin resistance — effects that are more pronounced in those with documented IR at baseline.

Fasting insulin and HOMA-IR monitoring — ideally annually for GG homozygotes — provides the earliest signal of progressing insulin resistance before it affects glucose tolerance. The TG/HDL-C ratio (elevated in G allele carriers per Tian 2020) is a readily available surrogate marker for atherogenic dyslipidemia and insulin resistance that can be tracked with a standard fasting lipid panel.

Interactions

rs2479106 (DENND1A): DENND1A is the strongest GWAS-replicated PCOS locus and acts through theca cell androgen biosynthesis. TOX3 rs4784165 and DENND1A rs2479106 appear to affect PCOS through different mechanisms — androgen production vs. insulin resistance — and women carrying risk alleles at both loci may face compounding PCOS severity across both hormonal and metabolic dimensions. No compound effect study has directly examined this combination.

rs13405728 (LHCGR): The LH/hCG receptor locus affects gonadotropin sensitivity in granulosa cells. Combined risk at LHCGR (elevated LH sensitivity) and TOX3 (impaired metabolic transcriptional regulation) may represent a pathway from hypothalamic-pituitary dysregulation to ovarian dysfunction, though no published study has examined these loci jointly.

Angiotensinogen (AGT)¹¹ Angiotensinogen (AGT)
the precursor protein for the entire renin-angiotensin-aldosterone system (RAAS) is produced primarily in the liver and released into the bloodstream, where renin cleaves it to angiotensin I. Angiotensin I is then converted by ACE into angiotensin II — the potent vasoconstrictor that raises blood pressure, promotes sodium retention, and drives cardiovascular remodeling. The rs5051 (G-6A) variant sits in the core promoter of the AGT gene, just 6 base pairs upstream of the transcription start site, where it acts as a molecular volume knob for angiotensinogen production.

The Mechanism

The AGT gene sits on the minus (reverse) strand of chromosome 1. In minus-strand notation, the variant is described as G-6A: a guanine-to-adenine substitution at position −6 relative to the transcription start. On the sequencing plus strand (what genome files report), this corresponds to a C-to-T change at rs5051.

The −6 position lies within the core promoter where transcription factors assemble to initiate RNA synthesis. Luciferase reporter assays²² Luciferase reporter assays
a standard molecular technique measuring how powerfully a DNA sequence drives gene expression demonstrate that the A allele at −6 (plus-strand T) drives significantly higher AGT transcriptional activity than the G allele — up to 68.6% more mRNA output³³ up to 68.6% more mRNA output. The adenine at this position likely alters the binding affinity of a transcription factor at or near the core promoter, sustaining higher rates of AGT mRNA synthesis. More AGT mRNA → more angiotensinogen protein → more substrate for renin → more angiotensin I → more angiotensin II → chronically elevated blood pressure.

The Evidence

Powell et al. 2024⁴⁴ Powell et al. 2024
Analysis of the combined effect of rs699 and rs5051 on angiotensinogen expression and hypertension. Chronic Dis Transl Med, 2024 analyzed 311,004 UK Biobank participants and found that rs5051 C>T associates with a 0.35 mmHg increase in systolic blood pressure per T allele (p<0.001). The effect was fourfold larger in Black participants (1.17 mmHg per allele, p=0.032) than in White participants (0.25 mmHg), consistent with the T allele's much higher frequency in African-ancestry populations. The study also confirmed in cell models that rs5051 T increases AGT transcription by up to 68.6% through altered transcription factor binding.

Gu et al. 2011⁵⁵ Gu et al. 2011
A-6G and A-20C Polymorphisms in the Angiotensinogen Promoter and Hypertension Risk in Chinese: A Meta-Analysis. PLoS One, 2011 pooled 15 studies comprising 3,442 hypertensive patients and 3,058 controls. Paradoxically, in Han Chinese populations where the T allele is very common (~83%), the dominant model showed the T (A at −6) allele was associated with lower hypertension risk (OR=0.71, 95%CI 0.57–0.87, p=0.001). Sex-specific analysis found protection was significant in women (OR=0.73) but not men. This apparently counterintuitive result likely reflects population-level confounding from linkage disequilibrium with other AGT haplotype variants, a pattern that differs between East Asian and European populations.

Chen et al. 2012⁶⁶ Chen et al. 2012
Promoter G-6A polymorphism associated with non-familial sick sinus syndrome. PLoS One, 2012 confirmed that the A allele at −6 produces higher AGT promoter transcriptional activity in luciferase assays and found that the G allele (lower AGT expression) was associated with sick sinus syndrome susceptibility — the complement of elevated-AGT effects on blood pressure.

Li et al. 2014⁷⁷ Li et al. 2014
AGT polymorphisms and essential hypertension in Northern Han Chinese. Angiology, 2014 found significantly different A-6G genotype distributions between 652 hypertensive patients and 780 controls (p<0.05) in a Chinese cohort, providing additional population-level evidence of the variant's role in essential hypertension susceptibility.

Practical Actions

Because rs5051 is tightly linked (r²=0.94) with rs699 (M235T), the two variants are almost always inherited together. Their combined effect on AGT expression and blood pressure is larger than either alone. Individuals carrying the T allele at rs5051 who also carry the G allele at rs699 have the highest angiotensinogen-driven blood pressure elevation.

For T allele carriers, the primary actionable implication is that a component of your blood pressure tends to be driven by genetically elevated angiotensinogen substrate supply to the RAAS. This means that RAAS-blocking medications — ACE inhibitors and angiotensin receptor blockers (ARBs) — target the precise upstream mechanism and may be particularly effective for blood pressure management in individuals with this genotype.

Dietary sodium restriction also exerts a larger effect on angiotensinogen-mediated blood pressure, since high sodium intake stimulates RAAS activity, compounding the elevated substrate supply.

Interactions

rs5051 and rs699 (AGT M235T) are almost universally co-inherited (r²=0.94) and function as a functional haplotype. rs5051 affects AGT transcription; rs699 changes the angiotensinogen protein sequence (Met235Thr), which independently affects angiotensinogen protein stability and plasma levels. The haplotype carrying rs5051-T + rs699-G produces the highest combined elevation in plasma angiotensinogen.

The RAAS as a whole is governed by several interacting variants: AGTR1 rs5186 (AT1 receptor, 3' UTR), ACE I/D rs4340 (ACE enzyme level), and CYP11B2 rs1799998 (aldosterone synthase). Individuals carrying multiple RAAS-elevating variants across these genes show compounding hypertension risk beyond the individual variant effects.

Every day your kidneys filter about 50 mg/dL of uric acid from the blood, but roughly 90% of that filtered urate gets reabsorbed — pulled back into the bloodstream before it can reach your urine. The single most important protein doing that reabsorption is URAT1¹¹ URAT1
Urate Transporter 1, encoded by SLC22A12 — the primary apical urate/anion exchanger in the renal proximal tubule. The rs505802 variant sits in the promoter region of SLC22A12 and influences how much URAT1 transporter your kidneys produce, directly setting the dial on how aggressively your body reclaims uric acid from the urine.

This makes rs505802 the third piece of a gout genetic panel alongside SLC2A9 (GLUT9, the basolateral urate transporter) and ABCG2 (the intestinal and renal secretory transporter). While SLC2A9 and ABCG2 variants alter the transporter protein itself, the SLC22A12 rs505802 variant operates upstream — it modulates the quantity of transporter produced rather than its per-molecule efficiency.

The Mechanism

rs505802 is located 2 kb upstream of SLC22A12 in the gene's regulatory region. The SLC22A12 promoter contains binding sites for HNF1α/β²² HNF1α/β
Hepatocyte nuclear factor 1 alpha and beta, transcription factors that drive kidney-specific URAT1 expression and estrogen response elements, both of which regulate tissue-specific expression. The C allele is associated with higher URAT1 expression and consequently greater renal urate reabsorption, while the T allele is associated with lower expression and more permissive urate excretion into the urine.

The variant is in near-perfect linkage disequilibrium (r² = 1 in Caucasians) with rs11231825 and rs11602903 in the SLC22A12 promoter region, meaning all three SNPs effectively tag the same functional haplotype. In African-ancestry populations, LD between these variants is lower, which is consistent with greater haplotype diversity.

URAT1 functions as an anion exchanger in the apical (luminal) membrane of proximal tubule cells: it swaps intracellular organic anions (lactate, nicotinate, pyrazinoate) for luminal urate, driving urate reabsorption. This is why URAT1 is the primary pharmacological target for uricosuric drugs — probenecid, lesinurad, benzbromarone, verinurad, and dotinurad all work by blocking this exchange, forcing more urate into the urine.

The Evidence

GWAS discovery and replication: The SLC22A12 locus was identified as genome-wide significant for serum uric acid in a meta-analysis of 28,141 Europeans (P = 2 × 10⁻⁹) Kolz et al., Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genetics, 2009³³ Kolz et al., Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genetics, 2009. Subsequent GWAS in Japanese (121,745 subjects, P = 1 × 10⁻³⁰⁰) and cross-ancestry cohorts (1,029,323 individuals, P = 5 × 10⁻³⁶⁰) confirmed rs505802 as one of the most robustly associated loci for serum urate in the human genome Cho et al., Large-scale cross-ancestry genome-wide meta-analysis of serum urate. Nature Communications, 2024⁴⁴ Cho et al., Large-scale cross-ancestry genome-wide meta-analysis of serum urate. Nature Communications, 2024.

Gout association: In 622 Han Chinese male gout cases and 917 controls, the T allele of rs505802 was protective against gout with an odds ratio of 0.747 (corrected P = 0.007), equivalent to a 25% reduction in gout risk per T allele Li et al., BMC Medical Genetics, 2015⁵⁵ Li et al., BMC Medical Genetics, 2015. A large PheWAS analysis confirmed the association: the T allele reduced gout risk with OR 0.86 (P = 1 × 10⁻⁹⁵) and was also associated with reduced gout medication use (P = 3 × 10⁻¹⁵) Verma et al., 2024⁶⁶ Verma et al., 2024.

Metabolic syndrome connection: In a study of 414 hypertensive patients, SLC22A12 promoter SNPs (including rs505802) explained 7% of BMI variation in Caucasians and were associated with metabolic syndrome (P = 0.033) Eraly et al., Kidney and Blood Pressure Research, 2012⁷⁷ Eraly et al., Kidney and Blood Pressure Research, 2012. This connects urate transport genetics to broader metabolic health beyond gout alone.

Effect size: The per-allele effect of rs505802 on serum urate is approximately −0.06 to −0.10 mg/dL per T allele across populations, with the largest effects observed in East Asian cohorts where the C allele is most prevalent. While smaller per-allele than SLC2A9, the population-level impact is substantial because of the high C allele frequency in non-European populations.

Practical Actions

The rs505802 genotype informs urate management through two key mechanisms: baseline risk stratification and pharmacological context. CC carriers have genetically elevated URAT1 expression, meaning their kidneys are programmed to reabsorb more uric acid. This creates a higher baseline that dietary purines, alcohol, and fructose push further upward.

For pharmacological context, CC carriers may respond more strongly to uricosuric drugs (probenecid, lesinurad, benzbromarone) because they have more URAT1 transporter to inhibit — this is the very target these drugs block. Conversely, TT carriers who already have lower URAT1 expression may derive less incremental benefit from uricosurics and might respond better to xanthine oxidase inhibitors (allopurinol, febuxostat) that reduce urate production instead.

Interactions

SLC2A9 (rs3733591) and ABCG2 (rs2231142): The three major urate transport genes — SLC22A12 (apical reabsorption via URAT1), SLC2A9 (basolateral reabsorption via GLUT9), and ABCG2 (apical secretion via BCRP) — operate at independent points in the renal urate handling pathway. Risk alleles at multiple loci compound additively. An individual carrying rs505802 CC, SLC2A9 rs3733591 CC, and ABCG2 rs2231142 TT has maximal urate reabsorption, minimal urate secretion, and substantially elevated gout risk beyond any single variant alone.

Estrogen and sex-specific effects: The SLC22A12 promoter contains estrogen response elements, and URAT1 expression is modulated by estrogen status. Pre-menopausal women have lower urate levels in part because estrogen suppresses URAT1 expression; post-menopausal women lose this protection. The rs505802 C allele effect may be amplified after menopause as estrogen-mediated transcriptional suppression of SLC22A12 is lost.

Uricosuric drug response: Probenecid, lesinurad, and benzbromarone all inhibit URAT1 directly. Individuals with higher URAT1 expression (CC genotype) have a larger pharmacological target for these drugs and may show a more robust uricosuric response. This pharmacogenomic relationship has not yet been confirmed in prospective clinical trials but is mechanistically well-supported.

The Fc gamma receptor IIa (FcγRIIa, encoded by FCGR2A) is the immune system's main sensor for IgG-coated threats. Displayed on the surface of macrophages, neutrophils, and dendritic cells, it binds the tail region (Fc) of IgG antibodies and triggers phagocytosis — the engulfing and destruction of bacteria, viral immune complexes, and cellular debris. rs511278 is an intronic variant in FCGR2A that sits within the same haplotype block¹¹ haplotype block
A segment of DNA inherited together because variants within it are in strong linkage disequilibrium — they rarely separate during recombination as the classical functional variant rs1801274 (H131R). The T allele at rs511278 co-segregates with the histidine-131 (H131) form of FcγRIIa — the receptor variant that binds IgG2 efficiently. The C allele at rs511278 co-segregates with the arginine-131 (R131) form, which barely binds IgG2 at all.

The Mechanism

The H131R substitution at position 131 of the mature FcγRIIa protein changes a histidine to an arginine in the second immunoglobulin-like domain²² immunoglobulin-like domain
A structural fold shaped like an antibody constant region domain; FcγRIIa has two of these Ig-like domains that directly contact the Fc region of IgG of the receptor. This single amino acid swap has a major functional consequence: H131 binds IgG2 and IgG3 efficiently, while R131 barely interacts with IgG2 at all — and IgG2 is the dominant antibody subclass produced against polysaccharide antigens on the surface of encapsulated bacteria like Streptococcus pneumoniae and Haemophilus influenzae.

The two alleles are co-dominantly expressed, meaning heterozygotes (CT at rs511278, corresponding to H131/R131) have intermediate receptor function between the two homozygous states. The T allele at rs511278 is the minor allele globally (~18%), but its frequency varies substantially by ancestry: ~21% in Europeans, ~12% in Africans, and only ~7% in East Asians.

Because rs511278 is intronic and not itself the functional change, the biological effects described here derive from its linkage disequilibrium³³ linkage disequilibrium
The statistical tendency for two nearby alleles to be inherited together; when LD is high, an intronic tag SNP reliably predicts which functional allele is present with rs1801274 (H131R). The T allele tags H131; the C allele tags R131.

The Evidence

The highest-confidence association is Kawasaki disease (KD), a vasculitis predominantly affecting children under 5 that causes coronary artery aneurysms. The 2011 landmark GWAS by Khor et al.⁴⁴ landmark GWAS by Khor et al.
Genome-wide association study identifies FCGR2A as a susceptibility locus for Kawasaki disease. Nature Genetics, 2011 — 2,173 KD cases and 9,383 controls across five international cohorts — identified rs1801274 as the lead SNP at this locus (P = 7.35×10⁻¹¹, OR = 1.32 per A allele). The A allele at rs1801274 corresponds to H131 — the same haplotype tagged by the T allele at rs511278. Higher IgG-mediated immune activation from H131 may contribute to the disproportionate vasculitis response in KD-susceptible children.

A meta-analysis of 6 KD studies⁵⁵ meta-analysis of 6 KD studies
Association between FCGR2A rs1801274 H131R polymorphism and risk of Kawasaki disease. PLoS ONE, 2015 with 1,709 cases and 3,207 controls found H/H homozygotes had OR = 1.97 (95% CI 1.55–2.50) versus R/R homozygotes. The association was significant in Asians but not Caucasians — consistent with the lower H131 (T allele) frequency in East Asians, where the variant is rarer and cases carrying it have a proportionally larger genetic signal.

The SLE picture is the mirror image⁶⁶ SLE picture is the mirror image
Comprehensive Assessment of FCGRs polymorphisms and SLE risk. Arthritis Research and Therapy, 2016: the A allele (H131, tagged by T at rs511278) is protective against overall SLE susceptibility (OR = 0.879 per A allele, P = 3.31×10⁻⁴), but the R131 allele (C at rs511278) is specifically associated with lupus nephritis severity in some populations. This apparent paradox reflects that H131's efficient IgG immune complex clearance protects against SLE development (preventing accumulation of inflammatory complexes) while paradoxically contributing to immune hyperactivation in conditions like KD.

For infectious disease, the consequence reverses again⁷⁷ consequence reverses again
Protective Effects of FCGR2A Polymorphism in Invasive Pneumococcal Diseases. Chest, 2012: R/R homozygotes (CC at rs511278) showed 75% lower hospital mortality in severe invasive pneumococcal disease (OR 0.251, P = .004). The proposed mechanism is that the H131 allele, while enabling better phagocytic clearance, may also drive a more intense and potentially damaging inflammatory response in severe systemic infections. Meanwhile, for pneumococcal vaccination⁸⁸ pneumococcal vaccination
Pneumococcal vaccine efficacy for mucosal infections depends on FcγRIIa polymorphism. Vaccine, 2005, the H131 allele is critical: R/R homozygotes show significantly higher recurrence of acute otitis media after pneumococcal vaccination, as IgG2 antibodies induced by the vaccine cannot efficiently engage R131 receptors on phagocytic cells.

In COVID-19, a 2022 ICU cohort study⁹⁹ 2022 ICU cohort study
FCGR2A rs1801274 polymorphism associated with risk of death among COVID-19 patients. Scientific Reports, 2022 found the G allele (R131) was associated with increased mortality (OR = 1.47), with the dominant model (GG + AG vs AA) yielding OR = 2.22. This aligns with the IgG2-clearing hypothesis: H131 carriers clear viral immune complexes more efficiently.

Practical Actions

The clinical picture is inherently bidirectional: the T allele (H131 haplotype) confers both immune advantages (better vaccination response, better viral and bacterial immune complex clearance) and immune risks (higher KD susceptibility, possible contribution to inflammatory overactivation). For TT homozygotes, awareness of KD family history and monitoring for autoimmune triggers is appropriate. For CC homozygotes (R131 haplotype), vaccine responses to IgG2-dependent immunizations (pneumococcal polysaccharide vaccines) may be attenuated, and infection surveillance is warranted.

Interactions

rs511278 is in the same haplotype block as rs1801274 (H131R missense), meaning these two SNPs typically co-occur and should be interpreted together. The functional variant rs396991 in FCGR3A (V158F, CD16a) operates through a complementary but distinct receptor pathway — FcγRIIIa is expressed on NK cells and mediates ADCC, while FcγRIIa on phagocytes mediates opsonophagocytosis. Combined low-affinity genotypes at both FCGR2A and FCGR3A may compound impaired IgG-mediated immune responses.

The X chromosome contains far fewer genes than autosomes, and its contribution to testosterone biology in men was largely overlooked until large genome-wide association studies began scanning the full genome including sex chromosomes. rs5934505 sits in the Xp22 region in a structural variant-rich zone between two genes, FAM9B and FAM9A¹¹ FAM9B and FAM9A
family with sequence similarity 9, members B and A — both encoded on the X chromosome and expressed exclusively in the testis, approximately 79 kb downstream of FAM9B and 145 kb upstream of FAM9A. Despite being in a gene-sparse intergenic region, this SNP has reached genome-wide significance for serum testosterone concentrations in men across multiple independent GWAS cohorts. It represents one of only a handful of replicated genetic loci influencing circulating testosterone levels.

The Mechanism

The precise molecular mechanism by which rs5934505 influences testosterone has not been established. Both FAM9B and FAM9A are expressed almost exclusively in the testis — specifically in spermatogenic cells — making them prime candidates for regulatory elements that govern Leydig cell androgen synthesis or spermatogenic feedback on testosterone production. As an intergenic variant in a known copy-number variable (CNV) region on Xp22, rs5934505 may tag a regulatory element affecting the transcription of one or both flanking genes, with downstream effects on steroidogenesis in testicular tissue. Because the locus is on the X chromosome, the effect is hemizygous in men — each male carries exactly one copy (T or C), with no heterozygous intermediate. Women carry two copies and can be TT, TC, or CC.

The T allele is the reference/major allele, present in approximately 73% of chromosomes globally. Despite being common, the T allele is associated with lower serum testosterone. This is an example of the common-variant, common-phenotype pattern where the major allele at a locus defines a disadvantageous baseline — the C allele (minor allele, ~27%) appears to be the ancestrally-derived testosterone-promoting variant retained at moderate population frequency by either selection or drift.

The Evidence

The primary discovery study, Ohlsson et al. 2011 (PLoS Genetics), conducted a GWAS meta-analysis across 10 independent cohorts totaling 14,429 Caucasian men²² Ohlsson et al. 2011 (PLoS Genetics), conducted a GWAS meta-analysis across 10 independent cohorts totaling 14,429 Caucasian men
Genetic determinants of serum testosterone concentrations in men, finding rs5934505 at a combined p=5.6×10⁻¹⁶ for total testosterone and calculated free testosterone — one of only two loci reaching genome-wide significance. Men with the T allele had lower mean serum testosterone than those with the C allele. The variant explained 0.6% of the variance in serum testosterone concentrations in the MrOS Sweden replication cohort, making it a modest but reliably detected effect at the population level.

Jin et al. 2012 (Human Molecular Genetics), examining 3,225 men in an Australian cohort, independently confirmed the FAM9B locus at genome-wide significance (p=1.61×10⁻⁸)³³ Jin et al. 2012 (Human Molecular Genetics), examining 3,225 men in an Australian cohort, independently confirmed the FAM9B locus at genome-wide significance (p=1.61×10⁻⁸)
Genome-wide association study identifies a new locus JMJD1C at 10q21 that may influence serum androgen levels in men. The same study also found a nominally significant association with dihydrotestosterone (DHT; p=1.10×10⁻⁵), suggesting the variant may influence the full androgen cascade rather than testosterone alone. The minor allele (C, ~28% MAF in this Australian cohort) was associated with higher levels.

A 2018 meta-analysis extending the search to circulating estrogen levels in men, Eriksson et al. 2018 (J Clin Endocrinol Metab)⁴⁴ Eriksson et al. 2018 (J Clin Endocrinol Metab)
Genetic determinants of circulating estrogen levels and evidence of a causal effect of estradiol on bone density in men, also identified rs5934505 at the FAM9B locus at genome-wide significance (p=3.4×10⁻⁸) for estradiol levels, suggesting this Xp22 locus may influence both androgen and estrogen concentrations — consistent with the biological link between testosterone and its aromatization product estradiol.

Practical Actions

For men carrying the T allele (the majority), awareness of this testosterone- lowering predisposition is most relevant when interpreting lab results in the context of symptoms of low testosterone — fatigue, reduced libido, loss of muscle mass, or mood changes. While the T allele's effect size (explaining ~0.6% of variance) is modest at the population level, it compounds with other testosterone-relevant loci (SHBG at rs727428, JMJD1C at rs10822184) and lifestyle factors (adiposity, sleep quality, zinc status, vitamin D) that all influence the same hormone. Men with borderline testosterone levels near the lower reference range may benefit from targeted testing and consideration of whether their genetic predisposition is compounding the effect.

For women, the X-linked nature means heterozygous TC carriers and homozygous CC carriers are expected to have different androgenic tone than TT homozygotes, though specific GWAS data for women at this locus are limited since the primary studies focused on male cohorts. The testis-exclusive expression of FAM9B and FAM9A suggests the primary mechanism is testicular in origin, with the X-linkage creating a dose asymmetry in women that may have milder hormonal consequences.

Interactions

Rs5934505 is one of a small set of confirmed testosterone-associated loci. The SHBG locus (rs727428, chromosome 17) is the strongest autosomal testosterone determinant through its regulation of sex hormone-binding globulin — which controls the ratio of free to total testosterone. The JMJD1C locus (rs10822184, chromosome 10) affects androgen levels through a different pathway. Men carrying the T allele at rs5934505 alongside testosterone-lowering variants at SHBG or JMJD1C may have compounded reductions in circulating androgen that approach the threshold for clinical concern.

CYP17A1 rs743572, which encodes a promoter variant of the rate-limiting steroidogenic enzyme, is in a separate category as it affects androgen precursor synthesis in the adrenal and gonadal steroidogenesis cascade. The FAM9B Xp22 locus is most likely acting through a distinct, testis-local mechanism rather than a shared pathway.

Your skin color is not simply on or off — it is the result of a molecular competition between two opposing signals in every melanocyte. On one side is α-melanocyte stimulating hormone (α-MSH), which binds the melanocortin-1 receptor (MC1R) and drives eumelanin (brown-black pigment) production. On the other side is agouti signaling protein (ASIP), a secreted antagonist that blocks MC1R and pushes melanocytes toward pheomelanin (red-yellow pigment). The rs6058017 variant in ASIP — located 25 bases downstream of the gene's stop codon in the 3' untranslated region — is a key dial controlling how much ASIP protein your melanocytes produce, and therefore how dark your constitutive pigmentation tends to be.

The Mechanism

The rs6058017 A>G substitution lies in the 3' untranslated region (3'UTR) of ASIP — the tail of the messenger RNA that controls transcript stability, translation efficiency, and protein output. The G allele (ancestral, more common in African populations) causes premature mRNA degradation and message instability¹¹ premature mRNA degradation and message instability
Voisey et al., 2006, quantitative RT-PCR in human skin biopsies. Cells carrying the AA genotype produce roughly 12 times more ASIP mRNA than cells carrying the AG genotype, meaning AA individuals flood their melanocytes with ASIP protein that actively suppresses eumelanin synthesis. In contrast, G allele carriers have less ASIP, leaving MC1R signaling relatively unopposed — α-MSH can bind freely, activate cAMP cascades, upregulate MITF and tyrosinase, and drive robust eumelanin production. The result is a genetically encoded tendency toward darker skin, hair, and eye color in G allele carriers.

The A allele, which rose to high frequency in European populations through positive selection, increases ASIP expression and tips the balance toward pheomelanin synthesis. Because pheomelanin provides substantially less UV photoprotection than eumelanin — and may even generate reactive oxygen species under UV irradiation that compound DNA damage — individuals with the AA genotype carry a constitutional vulnerability to ultraviolet injury despite appearing to have "normal" European-type skin.

The Evidence

The pigmentation associations of rs6058017 were first reported by Kanetsky et al. in 2002²² Kanetsky et al. in 2002
147 healthy Caucasian controls at the University of Pennsylvania, melanoma cases excluded. Carriage of the G allele was significantly associated with dark hair (OR 1.8, 95% CI 1.2–2.8) and brown eyes (OR 1.9, 95% CI 1.3–2.8) after adjustment for age and sex. Homozygous GG carriers showed an even stronger signal, though the small GG sample (n=9) limited statistical power. The functional basis for this association was established by Voisey et al. in 2006³³ Voisey et al. in 2006
Australian European and indigenous Australian skin biopsies, who used quantitative RT-PCR to demonstrate the 12-fold difference in mRNA abundance between AA and AG genotypes. The same study found the G allele significantly more frequent in indigenous Australians than European Australians, consistent with the ancestral nature of the G variant. A complementary study by Bonilla et al. in 2005⁴⁴ Bonilla et al. in 2005
234 African Americans, skin reflectometry confirmed that the 8818G allele was associated with darker objectively measured skin color, with particularly pronounced effects in women (P<0.001).

An important distinction: rs6058017 itself has a weak and inconsistent association with melanoma risk across studies — some show modest association, others show null results. The strong skin cancer signal in the ASIP locus comes from a separate upstream haplotype defined by rs1015362 and rs4911414⁵⁵ upstream haplotype defined by rs1015362 and rs4911414
located ~110 kb upstream of ASIP coding sequence, which reached genome-wide significance for cutaneous melanoma (OR 1.45, P=1.2×10⁻⁹) and BCC (OR 1.33, P=1.2×10⁻⁶) in 2,121 melanoma cases and over 40,000 controls. This haplotype is not in strong linkage disequilibrium with rs6058017 — the two signals are partially independent. Individuals with the rs6058017 A allele carry lighter pigmentation and the biologic rationale for elevated UV risk, but direct attribution of melanoma risk to this specific variant requires additional study.

Practical Implications

Your ASIP genotype shapes your constitutive (baseline) pigmentation level, which in turn determines how much photoprotection your skin's melanin provides against UV-induced DNA damage. Individuals with the AA genotype produce more ASIP, suppress eumelanin synthesis, and tend toward lighter skin that offers less natural UV shielding. The practical implication is dose-dependent UV protection regardless of whether you tan easily: broad-spectrum SPF 30+ sunscreen daily, protective clothing when outdoors for extended periods, and annual dermatologic skin checks for those with multiple light-pigmentation variants.

The GG genotype, more common in people of West African, South Asian, and East Asian ancestry, reflects ancestrally high ASIP suppression — producing constitutively darker, more photoprotective eumelanin-rich skin. This does not eliminate melanoma risk entirely (acral and mucosal melanomas occur across pigmentation types), but the UV-driven pathway to cutaneous melanoma is substantially less active.

Interactions

The most clinically relevant interaction is between ASIP and MC1R. ASIP acts as an endogenous competitive antagonist at MC1R — so variants that weaken MC1R signaling (such as rs1805007 R151C and rs1805008 R160W, associated with red hair) interact with ASIP variants in compound fashion: both reduce eumelanin output through different mechanisms. Individuals carrying the ASIP AA genotype (high ASIP, low eumelanin) together with MC1R red-hair-color variants (impaired MC1R, reduced cAMP response to α-MSH) face a dual eumelanin deficit that may substantially amplify UV vulnerability and melanoma risk. This interaction is worth noting for those with both a pale, poorly-tanning complexion and a family history of melanoma — the compound genotype warrants more aggressive photoprotection and surveillance.

Within the ASIP locus, the relationship between rs6058017 and the upstream haplotype (rs1015362, rs4911414) is also important to understand: these signals are partially independent, and individuals carrying both the ASIP haplotype risk alleles AND the rs6058017 A allele may carry compounded risk through distinct molecular mechanisms at the same locus.

Apolipoprotein A5 (APOA5) is a liver-secreted protein that acts as a critical regulator of circulating triglyceride levels. Though present in plasma at very low concentrations, APOA5 has an outsized effect on fat clearance¹¹ APOA5 has an outsized effect on fat clearance
Plasma APOA5 concentrations are 1,000-fold lower than APOA1 yet exert comparable effects on triglyceride metabolism by facilitating the activity of lipoprotein lipase (LPL)²² lipoprotein lipase (LPL)
The enzyme anchored to capillary walls that breaks down triglycerides in VLDL and chylomicrons, the enzyme responsible for breaking down fat-carrying particles in the bloodstream. The -1131T>C promoter variant (rs662799) reduces how much APOA5 the liver produces, weakening this clearance system and allowing triglycerides to accumulate in circulation.

The Mechanism

The -1131T>C change sits in the promoter region of the APOA5 gene, approximately 1,131 base pairs upstream of where gene transcription begins. The C allele (reported as the G allele on the forward genomic strand by 23andMe) impairs ribosomal translation efficiency³³ impairs ribosomal translation efficiency
In vitro studies show reduced translational efficiency of mRNA carrying the -1131C allele, resulting in lower circulating APOA5 protein levels. With less APOA5 available, LPL activity at the capillary surface is reduced⁴⁴ LPL activity at the capillary surface is reduced
APOA5 tethers LPL to heparan sulfate proteoglycans on capillary endothelium and stabilizes the enzyme, slowing the breakdown of triglyceride-rich lipoproteins (VLDL and chylomicrons). The result is slower postprandial triglyceride clearance and higher fasting triglyceride levels.

The effect is additive — each copy of the C (A on forward strand) risk allele progressively reduces APOA5 expression and raises triglycerides. The variant is part of the APOA5*2 haplotype⁵⁵ APOA5*2 haplotype
A group of co-inherited APOA5 promoter variants including rs662799, rs651821, rs2072560, and rs2266788 associated with hypertriglyceridemia susceptibility.

The Evidence

The rs662799 -1131C allele is one of the most replicated genetic determinants of circulating triglycerides in the human genome. A meta-analysis of 51,868 participants⁶⁶ meta-analysis of 51,868 participants
Including 46 East Asian studies, 26 European studies, and 19 studies of other ethnic groups confirmed the C allele raises fasting triglycerides by a weighted mean difference of 0.30 mmol/L (about 26 mg/dL) and increases metabolic syndrome risk with an OR of 1.33 (95% CI 1.16–1.53) in the overall population. In a Hong Kong and Guangzhou Chinese cohort, plasma triglycerides were 36.1% higher in CC versus TT homozygotes⁷⁷ plasma triglycerides were 36.1% higher in CC versus TT homozygotes
OR for hypertriglyceridemia ≥1.7 mmol/L was 2.22 (1.44–3.43) for CC and 1.81 (1.37–2.39) for TC.

The cardiovascular consequences are also significant. A meta-analysis of 49,806 individuals⁸⁸ meta-analysis of 49,806 individuals
21,378 CHD cases and 28,428 controls across 10 ethnic populations showed the C allele significantly increases coronary heart disease risk (OR ~1.27 at the allele level, P < 0.00001), with consistent effects across Chinese, other Asian, and Caucasian populations.

Practical Actions

The dietary implications of this variant are particularly clear. C allele carriers appear to have a blunted metabolic response to caloric restriction and dietary fat improvement⁹⁹ C allele carriers appear to have a blunted metabolic response to caloric restriction and dietary fat improvement
Caucasian obese subjects: TG reduction −19.3 vs −4.2 mg/dL in TT vs C carriers after Mediterranean diet intervention. In a study of 363 obese Caucasian subjects, TT homozygotes achieved significant reductions in triglycerides, insulin, and insulin resistance (HOMA-IR) on a hypocaloric Mediterranean-pattern diet, while C allele carriers showed no statistically significant improvement on any of these metabolic parameters.

The fat quality appears to matter more than quantity for C allele carriers. Specifically, high n-6 polyunsaturated fat intake exacerbates the adverse effect¹⁰¹⁰ high n-6 polyunsaturated fat intake exacerbates the adverse effect
Dietary n-6 PUFA intake modulates the APOA5 effect on plasma TG and remnant lipoprotein concentrations of the risk allele on triglycerides, suggesting that correcting an omega-6:omega-3 imbalance is especially important. Increasing EPA and DHA intake through fatty fish or high-dose fish oil supplements is the most evidence-based strategy for reducing triglycerides in C allele carriers whose lifestyle interventions have had limited effect.

Monitoring fasting triglycerides regularly allows early detection of deterioration before cardiovascular risk accumulates. A fasting TG above 1.7 mmol/L (150 mg/dL) is the threshold for the metabolic syndrome criterion and a reasonable alert level for C allele carriers to intensify dietary and supplementation efforts.

Interactions

The rs662799 variant is part of the APOA5*2 haplotype, which co-segregates with other APOA5 variants — notably rs651821 (-3A>G), rs2072560 (715G>T), and rs2266788 (1891T>C). These variants are in partial linkage disequilibrium and collectively define haplotype-level triglyceride risk. Having multiple APOA5 risk alleles compounds the effect.

APOA5 interacts with the APOE genotype in determining triglyceride clearance and cardiovascular risk. APOE4 carriers (rs429358) with a concurrent APOA5 risk allele may have amplified dyslipidemia because both proteins affect VLDL metabolism through overlapping but distinct pathways — APOE governs VLDL receptor binding while APOA5 controls LPL activity. Individuals with both variants may benefit most from aggressive triglyceride management.

The rs3135506 variant (APOA5*3, Ser19Trp) is separately and independently associated with hypertriglyceridemia through a different mechanism (reduced LPL binding affinity). Carrying both rs662799 and rs3135506 risk alleles represents a compounded impairment in triglyceride clearance capacity.

Interferon Regulatory Factor 5 (IRF5) is a master transcription factor for type I interferon production and proinflammatory cytokine secretion — a molecular switch that, when overactive, drives the chronic immune activation underlying systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, and Sjögren syndrome. rs729302 sits approximately 9 kilobases upstream of the IRF5 coding sequence in the 5' promoter region, where it serves as the key tag SNP¹¹ tag SNP
A variant in linkage disequilibrium with the true causal variant; used to track haplotypes when the causal site is unknown or difficult to genotype for a cluster of protective haplotypes that dampen interferon output. While rs10488631 (already documented separately) marks the 3' risk haplotype block that amplifies IRF5 activity, rs729302 marks an opposing 5' protective block — the other end of a molecular rheostat controlling how loudly your immune system broadcasts the interferon alarm.

The Mechanism

The rs729302 variant is an A-to-C substitution in the 5' regulatory region of IRF5. The common A allele is the reference (risk-direction) allele; the C allele is the minor allele that tags the protective haplotypes. In luciferase reporter gene assays using lymphoblastoid cells, the C allele showed borderline increased transcriptional activity and additional transcription factor binding relative to the A allele in electrophoretic mobility shift assays²² C allele showed borderline increased transcriptional activity and additional transcription factor binding relative to the A allele in electrophoretic mobility shift assays
Fernández-Hernández et al. 2013, Arthritis Research & Therapy; the functional difference was modest, suggesting rs729302 itself may not be causal but rather tags a nearby causal regulatory element.

The protective haplotypes tagged by rs729302-C reside in the 5' side of the IRF5 locus and are functionally distinct from — and independent of — the three-block risk haplotype system anchored by rs2004640, the exon 6 INDEL, and rs10488631. Conditional analysis in the landmark 14-cohort European SLE study demonstrated that the protective signal from rs729302 persisted after conditioning on all known susceptibility variants³³ persisted after conditioning on all known susceptibility variants
Including rs10488631, rs2004640, and the CGGGG promoter indel — indicating the protective signal is not simply an absence of risk alleles, establishing it as a genuinely independent protective locus within the gene. Subsequent work in the comprehensive HMG haplotype study found that the rs729302 association signal is partially explained by linkage disequilibrium with the CGGGG insertion-deletion polymorphism⁴⁴ linkage disequilibrium with the CGGGG insertion-deletion polymorphism
A 5-bp indel in the IRF5 promoter that creates or destroys an Sp1 transcription factor binding site, altering basal IRF5 transcription, but the variant remains the best available tag SNP for this protective haplotype block on current genotyping arrays.

The Evidence

The foundational evidence for rs729302 comes from the same landmark 14-cohort European study that identified rs10488631 as the leading IRF5 susceptibility signal. Examining 1,383 SLE cases and 1,614 controls, Ferreiro-Neira et al. found that two SNPs at the IRF5 locus showed independent and opposed associations⁵⁵ two SNPs at the IRF5 locus showed independent and opposed associations
Susceptibility: rs10488631, P<10⁻¹⁷; protection: rs729302, P<10⁻⁶. The protective signal from rs729302 was statistically independent of the susceptibility signal, meaning individuals can carry both — their net interferon tone reflecting a balance between the two haplotype blocks.

The protective direction is consistent across diseases and populations. In rheumatoid arthritis, a meta-analysis of five case-control studies (6,582 RA cases and 5,375 controls)⁶⁶ meta-analysis of five case-control studies (6,582 RA cases and 5,375 controls)
Han et al. 2009, Journal of Rheumatology confirmed the C allele is protective (random-effects OR=0.889, 95% CI 0.803–0.977, P=0.015). The same study found that allele frequencies differ meaningfully between cases and controls — the C allele is enriched in the healthy population relative to disease patients, a pattern seen across cohorts.

In Korean SLE patients, rs729302 showed the same directionality: the A allele was enriched in cases (frequency 0.729) compared to controls (frequency 0.680), yielding OR=1.27 (95% CI 1.08–1.49, P=0.0037)⁷⁷ OR=1.27 (95% CI 1.08–1.49, P=0.0037)
Shin et al. 2007, Arthritis Research & Therapy; Korean study mirroring European findings for the risk A allele. In Japanese RA patients, the A allele showed OR=1.22 (P<0.001) for disease susceptibility, with a particularly strong effect in HLA shared-epitope-negative patients (OR=1.50), suggesting rs729302 captures a distinct autoimmune pathway⁸⁸ suggesting rs729302 captures a distinct autoimmune pathway
One independent of the classical HLA shared epitope mechanism that dominates seropositive RA.

The C allele frequency in controls (approximately 32% in Europeans) versus cases (approximately 27%) in the Swedish SLE cohort represents a meaningful enrichment of the protective allele in the healthy population — quantitatively modest per allele, but clinically meaningful across a locus with such broad autoimmune relevance.

Practical Implications

Carrying one or two copies of the C allele at rs729302 indicates your IRF5 locus carries partial or full protective haplotype coverage in the 5' regulatory region. This does not confer immunity to autoimmune disease — environmental triggers, other genetic variants (including the 3' risk haplotype tagged by rs10488631), and stochastic immune events all play important roles. However, the C allele is measurably associated with lower interferon output and reduced disease susceptibility across multiple autoimmune conditions.

The most clinically relevant implication is in the context of the full IRF5 haplotype: individuals who carry the rs729302-C protective allele alongside the rs10488631-T (non-risk) allele have the lowest IRF5-mediated autoimmune risk, while those who carry rs729302-A alongside rs10488631-C face the highest. The intermediate scenarios — carrying protective alleles at one locus and risk alleles at the other — result in partially offsetting effects on interferon tone.

Interactions

rs729302 operates in the same IRF5 locus as rs2004640 (exon 1B splice site, documented separately) and rs10488631 (3' haplotype tag, documented separately). The three-block haplotype structure of IRF5 means individuals carry combinations of haplotypes across all three blocks simultaneously. The rs729302 protective haplotype is functionally and statistically independent of the rs10488631 susceptibility haplotype — they can coexist in the same genome, and the individual's net interferon phenotype reflects the sum of contributions across all three blocks.

The IRF5 locus also interacts additively with STAT4 (rs7574865), which encodes the signal transducer downstream of type I interferon. IRF5 drives interferon production; STAT4 amplifies cellular responsiveness to that interferon. rs729302-C carriers who also carry the STAT4 rs7574865 non-risk (CC) genotype have a double buffer — reduced production and reduced responsiveness — giving the most protected interferon pathway configuration.